MedTrace Logo

Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure

NCT00416663 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-09-03

No results posted yet for this study

Summary

Evaluation of an intracoronary injection of ex-vivo generated autologous Angiogenic Cells Precursors (ACPs) to treat patients suffering from severe angina not responsive to maximal drug treatment or not willing or without option of undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). The use of ACPs aims to promote the formation of new vascularization and thus viable myocardial tissue.

Conditions

  • Angina Pectoris

Interventions

PROCEDURE

Intracoronary administration of autologous ACPs

Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment

Sponsors & Collaborators

  • TheraVitae Ltd.

    lead INDUSTRY

Principal Investigators

  • Dan Tzivoni, MD · Director, Department of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2007-08-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00416663 on ClinicalTrials.gov